Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-17

Clinical Trial Update: Trial of TRC105 and Sorafenib in Patients With HCC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TRC105 plus sorafenib in hepatocellular carcinoma (PHASE 1/2) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)
  • TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-17